Dr. Michael C. Topf
Claim this profileVanderbilt University/Ingram Cancer Center
Studies Skin Cancer
Studies Squamous Cell Carcinoma
3 reported clinical trials
9 drugs studied
Area of expertise
1Skin Cancer
Stage IV
ctHPVDNA positive
p16 positive
2Squamous Cell Carcinoma
Stage IV
Affiliated Hospitals
Clinical Trials Michael C. Topf is currently running
89Zr Panitumumab PET/CT Imaging
for Head and Neck Cancer
The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr 89 panitumumab \[89Zr panitumumab\]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places in the body (metastasis) in patients with head and neck squamous cell carcinoma. Traditional PET/CT has a low positive predictive value for diagnosing metastatic disease in head and neck cancer. 89Zr panitumumab is an investigational imaging agent that contains radiolabeled anti-EGFR antibody which is overexpressed in head and neck cancer. The main question this study aims to answer is the sensitivity and specificity of 89Zr panitumumab for the detection of indeterminate metastatic lesions in head and neck cancer. Participants will receive 89Zr panitumumab infusion and undergo 89Zr panitumumab PET/CT 1 to 5 days after infusion. Participants will otherwise receive standard of care evaluation and treatment for their indeterminate lesions. Researchers will compare the 89Zr panitumumab to standard of care imaging modalities (magnetic resonance imaging (MRI), CT, and/or PET/CT).
Recruiting1 award Phase 1
Reduced-Dose Radiation Therapy
for Oropharyngeal Cancer
This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer. HPV positive oropharyngeal cancer has a better prognosis than oropharyngeal cancer not caused by HPV. A standard of care treatment for HPV positive oropharyngeal cancer is transoral robotic surgery followed by radiation therapy. However, this treatment is associated with many long-term side effects including difficulty swallowing. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving reduced dose radiation therapy after transoral robotic surgery may improve swallowing outcomes and quality of life compared to standard of care dose radiation therapy after transoral robotic surgery.
Recruiting1 award Phase 2
More about Michael C. Topf
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael C. Topf has experience with
- Positron Emission Tomography
- Zirconium Zr 89 Panitumumab
- Radiation Therapy
- Computed Tomography (CT)
- Imaging Agent
- Neck Dissection
Breakdown of trials Michael C. Topf has run
Skin Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Oropharyngeal Cancer
Oropharyngeal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael C. Topf specialize in?
Michael C. Topf focuses on Skin Cancer and Squamous Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are ctHPVDNA positive.
Is Michael C. Topf currently recruiting for clinical trials?
Yes, Michael C. Topf is currently recruiting for 2 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Michael C. Topf has studied deeply?
Yes, Michael C. Topf has studied treatments such as Positron Emission Tomography, Zirconium Zr 89 Panitumumab, Radiation Therapy.
What is the best way to schedule an appointment with Michael C. Topf?
Apply for one of the trials that Michael C. Topf is conducting.
What is the office address of Michael C. Topf?
The office of Michael C. Topf is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.